ANKRD22

Across TCGA pan-cancer cohorts, ANKRD22 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ANKRD22 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ANKRD22 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ANKRD22 expression acts as an unfavorable survival marker, although some lineages such as UCEC and PDAC show a favorable association.

UCEC, COAD, and PDAC are the cancer types where ANKRD22 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Quartile	All	1.000	0.728	.002	34	view →
COAD	DFS	Median	III,IV	0.891	1.000	.032	30	view →
PDAC	DFS	Quartile	III,IV	0.977	0.451	.006	13	view →
HNSC	OS	Median	III,IV	0.919	0.778	.014	12	view →
LSCC	DFS	Tertile	All	0.866	0.421	.044	3	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	3	view →
CCRCC	OS	Tertile	III,IV	0.599	1.000	.014	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ANKRD22–UCEC (OS)

Open the UCEC breakdown →